Ole Henrik Bang-Andreasen
AVANT BIO has promoted Ole Henrik Bang-Andreasen to Partner, elevating a key member of its investment team as the growth equity firm expands its focus on technologies supporting the next generation of therapeutics.
The promotion reflects Bang-Andreasen’s contributions to the firm’s investment strategy, portfolio company development and international expansion efforts, particularly across Europe’s growing life sciences ecosystem. AVANT BIO specializes in growth-stage investments in therapeutic-enabling technologies, including companies operating at the intersection of life sciences, health technology and emerging TechBio markets.
Since joining the firm ahead of the launch of its second fund, Bang-Andreasen has played a significant role in sourcing investment opportunities, supporting portfolio companies and strengthening relationships across the global life sciences sector. His work has also helped expand AVANT BIO’s presence in Europe, where biotechnology innovation and therapeutic development continue to attract increasing investor interest.
“Ole joined AVANT BIO ahead of our Fund II launch and has been an integral part of our investment team and our strategy development,” said Daniella Kranjac, Founding General Partner at AVANT BIO. “Ole has demonstrated exceptional leadership in both day-to-day and strategic initiatives and has made significant contributions to the growth and scaling of our firm.”
The promotion comes as investors increasingly target companies that provide the tools, platforms and infrastructure supporting drug discovery, development, manufacturing and delivery. Rather than investing directly in therapeutic products, firms like AVANT BIO focus on enabling technologies that help accelerate innovation across the broader healthcare and biotechnology landscape.
Bang-Andreasen has spent the past decade investing in life sciences companies across both public and private markets, with experience spanning company formation, growth financing and public offerings. Before joining AVANT BIO, he held roles at Tower House Partners, ABG Sundal Collier and Game Creek Capital, where he focused on healthcare and life sciences investments.
At AVANT BIO, he currently serves on the boards of portfolio companies PL BioScience, Abbelight and PathPresenter. The firm said he has played an important role in evaluating emerging technologies, supporting founders and helping portfolio companies navigate growth and commercialization opportunities.
“I am looking forward to continuing the work on making AVANT BIO the premier financier of growth-stage Life Science Industrials companies across the globe, and to continue building the AVANT BIO brand in this exciting sector,” Bang-Andreasen said.
His appointment to Partner underscores AVANT BIO’s emphasis on expanding its leadership team as competition intensifies for investments in therapeutic-enabling technologies. Areas such as advanced research tools, laboratory automation, AI-enabled drug discovery, biologics manufacturing and precision medicine infrastructure have attracted growing investor attention as pharmaceutical and biotechnology companies seek more efficient pathways to bring therapies to market.
Beyond his investment career, Bang-Andreasen has demonstrated leadership in competitive athletics. He represented Norway as a national team rower, captained Northeastern University’s men’s rowing team and competed professionally as a cyclist with Trinity Racing.
Founded as a growth equity firm focused on life sciences innovation, AVANT BIO invests in companies developing technologies that support how therapies are discovered, developed, manufactured and delivered. The firm’s investment strategy spans therapeutic enabling technologies, HealthTech and TechBio, sectors that continue to benefit from increasing demand for tools that improve efficiency and accelerate scientific advancement.
As the life sciences industry undergoes rapid technological transformation, AVANT BIO’s promotion of Bang-Andreasen highlights the firm’s commitment to strengthening its investment leadership and expanding its reach across global innovation hubs.